Drugs / LY377604
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00993421 | Oct 2009 → Jun 2010 | obesity disorder | Eli Lilly and Company | Terminated | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LY377604 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00993421 ↗ |
| Action | Activate | “Beta-3 adrenergic receptor agonist” CHEMBL2012520 ↗ |
| Action | Inhibit | “Beta-2 adrenergic receptor antagonist” CHEMBL2012520 ↗1“Beta-1 adrenergic receptor antagonist” CHEMBL2012520 ↗ |
| Modality | Small molecule | — CHEMBL2012520 ↗ |
| Route | Oral | “Given daily, orally for 24 weeks” NCT00993421 ↗ |
| Target | ADRB1 | “Beta-1 adrenergic receptor antagonist” CHEMBL2012520 ↗ |
| Target | ADRB2 | “Beta-2 adrenergic receptor antagonist” CHEMBL2012520 ↗ |
| Target | ADRB3 | “Beta-3 adrenergic receptor agonist” CHEMBL2012520 ↗ |